Characteristics of fibroid nodes in dynamics when using multiphasic and monophasic combined hormonal contraceptives

Abstract

BACKGROUND: The increasing prevalence of uterine fibroids at the age of 20–35 years and late fertility intentions are modern trends in women’s lives. Combined hormonal contraceptives level out cyclic fluctuations of sex steroids in the natural menstrual cycle; can be used by patients with fibroid nodes for contraception; and have a protective effect on uterine fibroids. The literature does not provide comparative data on the use of multi- and monophasic combined hormonal contraceptives with ethinyl estradiol by patients with uterine fibroids.

AIM: The aim of this study was to assess the characteristics of fibroid nodes in dynamics in women using multiphasic and monophasic combined hormonal contraceptives.

MATERIALS AND METHODS: This study included 554 women. Prospective part of the research involved 118 patients with uterine fibroids without indications for surgical treatment: 54 patients used multiphasic (ethinyl estradiol and desogestrel) and monophasic (ethinyl estradiol and various gestagens) combined hormonal contraceptives, and 64 patients did not. Who underwent pelvic ultrasound examination three times over 12 months. Retrospective part of the research included analysis of in-person instrumental-clinical-anamnestic data obtained from 436 women (45 patients with fibroid nodes and 391 healthy individuals). Out of the 391 healthy participants, 297 ones used various combined hormonal contraceptives with ethinyl estradiol for 1–30 years, while the other 94 did not.

RESULTS: In women with uterine fibroids using various combined hormonal contraceptives with ethinyl estradiol (n = 94), no changes in the sizes of classification of International Federation of Gynaecology and Obstetrics (FIGO) types 3 to 6 fibroid nodes were observed (n = 124; 21.7 ± 2.8 vs. 21.5 ± 3.2 mm; p > 0.05). In patients with FIGO type 4 fibroid nodes using multiphasic combined hormonal contraceptives (n = 20), a decrease in the size of the nodes was registered after 12 months (n = 14; 15.7 ± 3.4 vs. 14.1 ± 2.7 mm; p < 0.05). In 17 (5.7%) healthy participants using combined hormonal contraceptives and in 15 (16.0%) patients without fibroid nodes who did not use these drugs, uterine fibroids were first diagnosed in the reproductive period.

CONCLUSIONS: The use of various combined hormonal contraceptives by patients with uterine fibroids did not lead to an increase in the size of FIGO types 3 to 6 fibroid nodes with an initial diameter of up to 22 mm. After 12 months, we noted a decrease in the size of F4 type fibroid nodes with an initial diameter of up to 16 mm for the women with uterine fibroids, who took multiphasic combined hormonal contraceptives. In women of reproductive age who used combined hormonal contraceptives for 1–30 years, uterine fibroids were first diagnosed 2.8 times less often than in patients who did not use these drugs.

Keywords

uterine fibroids / fibroid nodes / combined hormonal contraceptives

References

[1] Arutyunova EE, Katkova AS, Rapoport SI. Ethnogeography of uterine fibroids: epidemiology, age and racial differences, types of surgical interventions. Consilium Medicum. 2018;20(6):26–30. (In Russ.) EDN: UZEXJI doi: 10.26442/2075-1753_2018.6.26-30

[2] Арутюнова Е.Э., Каткова А.С., Буралкина Н.А. Этногеография миомы матки: эпидемиология, возрастные и расовые различия, виды оперативных вмешательств // Consilium Medicum. 2018. Т. 20, № 6. С. 26–30. EDN: UZEXJI doi: 10.26442/2075-1753_2018.6.26-30

[3] Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433–2442. doi: 10.1210/en.2009-1225

[4] Ishikawa H., Ishi K., Serna V.A., et al. Progesterone is essential for maintenance and growth of uterine leiomyoma // Endocrinology. 2010. Vol. 151, № 6. P. 2433–2442. doi: 10.1210/en.2009-1225

[5] Tikhomirov AL. Myoma. Pathogenetic rationale for organpreserving treatment. Moscow: Meditsina; 2013. 319 p. (In Russ.)

[6] Тихомиров А.Л. Миома. Патогенетическое обоснование органосохраняющего лечения. Москва: Медицина, 2013. 319 с.

[7] Russian Society of Obstetricians and Gynecologists. Uterine fibroids. Clinical guidelines. Moscow: Ministry of Health of the Russian Federation; 2020. (In Russ.) [cited 2024 Sep 12] Available from: https://cr.minzdrav.gov.ru/schema/257_1

[8] Российское общество акушеров-гинекологов. Миома матки. Клинические рекомендации. Москва: Минздрав РФ, 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/257_1 Дата обращения: 12.09.2024.

[9] Russian Society of Obstetricians and Gynecologists. Abnormal uterine bleeding. Clinical guidelines. Moscow: Ministry of Health of the Russian Federation; 2021. (In Russ.) [cited 2024 Sep 12] Available from: https://cr.minzdrav.gov.ru/schema/645_1

[10] Российское общество акушеров-гинекологов. Аномальные маточные кровотечения. Клинические рекомендации. Москва: Минздрав РФ, 2021. Режим доступа: https://cr.minzdrav.gov.ru/schema/645_1 Дата обращения: 12.09.2024.

[11] Qin J, Yang T, Kong F, et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013;288(1):139–148. EDN: OMLPKV doi: 10.1007/s00404-013-2797-9

[12] Qin J., Yang T., Kong F., et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies // Arch Gynecol Obstet. 2013. Vol. 288, N 1. P. 139–148. EDN: OMLPKV doi: 10.1007/s00404-013-2797-9

[13] Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666

[14] Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions // Int J Gynecol Obstet. 2018. Vol. 143, N 3. P. 393–408. doi: 10.1002/ijgo.12666

[15] World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015. [cited 2024 Sep 12]. Available from: https://iris.who.int/bitstream/handle/10665/326788/9789289052689-rus.pdf?sequence=3

[16] Всемирная Организация Здравоохранения. Медицинские критерии приемлемости для использования методов контрацепции. 5-е изд. Женева: Всемирная Организация Здравоохранения, 2015. Режим доступа: https://iris.who.int/bitstream/handle/10665/326788/9789289052689-rus.pdf?sequence=3 Дата обращения: 12.09.2024

[17] Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists, Russian Society of Contraception; Sukhikh GT, Prilepskaya VN, editors. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical criteria for the acceptability of the use of contraceptive methods, WHO, 5th edition, 2015”. Moscow; 2023. [cited 2024 Sep 12] Available from: https://phlebounion.ru/files/uploads/News/files/2023%20Национальные%20критерии%20приемлемости%20контрацепции%202023.pdf

[18] ФГБУ НМИЦ акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Министерства Здравоохранения РФ, Российское общество акушеров-гинекологов, Российское общество по контрацепции. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ. 5-е изд., 2015» / под ред. Г.Т. Сухих, В.Н. Прилепской. Москва, 2023. Режим доступа: https://phlebounion.ru/files/uploads/News/files/2023%20Национальные%20критерии%20приемлемости%20контрацепции%202023.pdf. Дата обращения: 12.09.2024.

[19] Shapovalov AG. Differentiated approach to surgical tactics and postoperative rehabilitation for large uterine myoma in women of reproductive age [dissertation]. Donetsk; 2022. (In Russ.) [cited 2024 Sep 12] Avaliable from: https://vak.mondnr.ru/wp-content/uploads/2020/Avtoreferat/avtoreferat_Shapovalov.pdf

[20] Шаповалов А.Г. Дифференцированный подход к хирургической тактике и послеоперационной реабилитации при миоме матки больших размеров у женщин репродуктивного возраста: дис. … канд. мед. наук. Донецк, 2022. Режим доступа: https://vak.mondnr.ru/wp-content/uploads/2020/Avtoreferat/avtoreferat_Shapovalov.pdf Дата обращения: 12.09.2024.

[21] Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Ginecol Obstet. 2020;149(1):3–9. EDN: BWMGGA doi: 10.1002/ijgo.13102

[22] Giuliani E., As-Sanie S., Marsh E.E. Epidemiology and management of uterine fibroids // Int J Ginecol Obstet. 2020. Vol. 149, N 1. P. 3–9. EDN: BWMGGA doi: 10.1002/ijgo.13102

[23] Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Molec Cell Endocrinol. 2012;358(2):223–231. EDN: PMQAJR doi: 10.1016/j.mce.2011.05.044

[24] Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma // Molec Cell Endocrinol. 2012. Vol. 358, N 2. P. 223–231. EDN: PMQAJR doi: 10.1016/j.mce.2011.05.044

[25] Tyurina AA, Yashhuk AG, Imelaeva AG, et al. The role of progesterone and tissue growth factors in the pathogenesis of uterine fibroids. Practical medicine. 2018;16(6):124–129. (In Russ.) EDN: VBNXCU doi: 10.32000/2072-1757-2018-16-6-124-129

[26] Тюрина А.А., Ящук А.Г., Имельаева А.Г., др. Роль прогестерона и тканевых факторов роста в патогенезе миомы матки // Практическая медицина. 2018. Т. 16, № 6. С. 124–129. EDN: VBNXCU doi: 10.32000/2072-1757-2018-16-6-124-129

[27] Dobroxotova YuE, Xachatryan AS, Ibragimova DM. Uterine fibroids. Modern issues of pathogenesis and drug reduction therapy. Doctor.ru. 2013;7(85):29–32. (In Russ.) EDN: RDIITT

[28] Доброхотова Ю.Э., Хачатрян А.С., Ибрагимова Д.М. Миома матки. Современные вопросы патогенеза и медикаментозной редукционной терапии // Доктор.Ру. 2013. № 7(85). С. 29–32. EDN: RDIITT

[29] Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25–40 years. Acta Obstet Gynecol Scand. 2000;79(3):202–207.

[30] Borgfeldt C., Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25–40 years // Acta Obstet Gynecol Scand. 2000. Vol. 79, N 3. P. 202–207.

[31] Dolinskij AK. Efficiency of infertility treatment using myomectomy with different surgical approaches [dissertation]. Saint Petersburg; 2013. (In Russ.) [cited 2024 Sep 12] Avaliable from: https://www.dissercat.com/content/effektivnost-lecheniya-besplodiya-pri-vypolnenii-miomektomii-razlichnymi-khirurgicheskimi-do EDN: EPVBHX

[32] Долинский А.К. Эффективность лечения бесплодия при выполнении миомэктомии различными хирургическими доступами: дисс. … канд. мед. наук. Санкт-Петербург, 2013. Режим доступа: https://www.dissercat.com/content/effektivnost-lecheniya-besplodiya-pri-vypolnenii-miomektomii-razlichnymi-khirurgicheskimi-do. Дата обращения: 12.09.2024. EDN: EPVBHX

[33] Sopova YuI. Optimization of endoscopic methods of treatment of uterine fibroids in women of reproductive age [dissertation]. Moscow; 2021. (In Russ.) [cited 2024 Sep 12] Avaliable from: https://www.dissercat.com/content/optimizatsiya-endoskopicheskikh-metodov-lecheniya-miomy-matki-u-zhenshchin-reproduktivnogo EDN: OTJNUS

[34] Сопова Ю.И. Оптимизация эндоскопических методов лечения миомы матки у женщин репродуктивного возраста: дисс. … канд. мед. наук. Москва, 2021. Режим доступа: https://www.dissercat.com/content/optimizatsiya-endoskopicheskikh-metodov-lecheniya-miomy-matki-u-zhenshchin-reproduktivnogo. Дата обращения: 12.09.2024. EDN: OTJNUS

[35] Federal State Statistics Service; Okladnikov SM, Nikitina SYu, editors. Healthcare in Russia 2023. Statistical Digest. Moscow; 2023. (In Russ.)

[36] Федеральная служба государственной статистики. Здравоохранение в России 2023. Статистический сборник / под ред. С.М. Окладникова, С.Ю. Никитиной. Москва, 2023. 179 с.

[37] Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clinical Research Ed). 1986;293(6543):359–362. doi: 10.1136/bmj.293.6543.359

[38] Ross R.K., Pike M.C., Vessey M.P., et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives // Br Med J (Clinical Research Ed). 1986. Vol. 293, N 6543. P. 359–362. doi: 10.1136/bmj.293.6543.359

[39] Chiaffarino F, Parazzini F, Vecchia La C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999;106(8):857–860. doi: 10.1111/j.1471-0528.1999.tb08409.x

[40] Chiaffarino F., Parazzini F., Vecchia La C., et al. Use of oral contraceptives and uterine fibroids: results from a case-control study // Br J Obstet Gynaecol. 1999. Vol. 106, N 8. P. 857–860. doi: 10.1111/j.1471-0528.1999.tb08409.x

[41] Tikhomirov AL, Ledenkova AA, Bataeva AE. Pathogenetic justification of fibroids prevention. Problems of Gynecology, Obstetrics and Perinatology. 2011;10(1):75–78. (In Russ.) EDN: OIOPJJ

[42] Тихомиров А.Л., Леденкова А.А., Батаева А.Е. Патогенетическое обоснование профилактики миомы матки // Вопросы гинекологии, акушерства и перинатологии. 2011. Т. 10, № 1. С. 75–78. EDN: OIOPJJ

RIGHTS & PERMISSIONS

Eсо-Vector